earnings
confidence high
sentiment positive
materiality 0.80
Biogen Q3 revenue $2.5B (+3% YoY); non-GAAP EPS $4.81 (+18%); FY25 guidance raised
BIOGEN INC.
2025-Q3 EPS
reported $9.14
vs consensus $3.96
▲ beat
(+130.8%)
- GAAP diluted EPS $3.17 (+19% YoY); Non-GAAP diluted EPS $4.81 (+18% YoY).
- Launch products LEQEMBI ($121M, +82%), SKYCLARYS ($133M, +30%), ZURZUVAE ($55M) all show strong growth.
- Full year 2025 revenue guidance raised to flat to +1% (constant currency); Non-GAAP EPS guided $14.50-$15.00.
- Pipeline: LEQEMBI IQLIK approved, high-dose nusinersen resubmitted (PDUFA Apr'26), litifilimab Phase 3 fully enrolled (data H2'26).